Results 21 to 30 of about 2,024 (91)

Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations

Frontiers in Pharmacology, 2021
Development of new drugs is a time-taking and expensive process. Comprehensive efforts are being made globally toward the search of therapeutics against SARS-CoV-2.
Faez Iqbal Khan, Tongzhou Kang, Haider Ali, Dakun Lai   +3 more
doaj   +1 more source

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj   +1 more source

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters

International Journal of Pharmaceutics: X, 2021
Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels ...
Sawittree Sahakijpijarn, Chaeho Moon, Zachary N. Warnken, Esther Y. Maier, Jennie E. DeVore, Dale J. Christensen, John J. Koleng, Robert O. Williams, III   +7 more
doaj   +1 more source

Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials

Frontiers in Pharmacology, 2022
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu, Zhenchao Wu, Zhifei Han, Zhifei Han, Beibei Liu, Beibei Liu, Ning Shen, Ning Shen   +7 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj   +1 more source

Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters

Pharmaceutics, 2021
Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies, Jörg König, Ute Hofmann, Charlotte Kölz, Martin F. Fromm, Matthias Schwab   +5 more
doaj   +1 more source

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2023
Background Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs.
Chuizhe Chen, Junde Fang, Shu Chen, Mamy Jayne Nelly Rajaofera, Xuemiao Li, Bo Wang, Qianfeng Xia   +6 more
doaj   +1 more source

Effects of Remdesivir on in-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected COVID-19: A Propensity Score-Matched Study

Acta Medica Iranica, 2022
Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi, Ali Ajam, Mahnaz Montazeri, Samira Kafan, Abdolazim Veisizadeh, Morteza Ghoghaei, Sina Kazemian, Arezoo Ahmadi, Fazeleh Majidi, Maryam Moghadasi, Mehdi Kashani, Faezeh Ghasemi, Marzieh Pazoki   +12 more
doaj   +1 more source

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Trials, 2021
Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases.
Stephen I. Walimbwa, Julian P. Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D’Avolio, Mohammed Lamorde   +5 more
doaj   +1 more source

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Clinical and Translational Science, 2022
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon‐Jung Park, Seong Woo Choi, Kiwon Ban, Sung‐Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith   +30 more
doaj   +1 more source